icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022
Back grey_arrow_rt.gif
 
 
 
Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection
 
 
  European Association for the Study of the Liver (EASL): International Liver Conference 22-26 June 2002; London, England
 
oral presentation
 
Young-Suk Lim,1 Man-Fung Yuen,2 Daniel Cloutier,3 Vaidehi Thanawala,3 Ling Shen,3 Sneha V. Gupta,3 Andre Arizpe,3 Andrea L. Cathcart,3 Carey Hwang,3 Edward Gane4
 
1Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; 2Queen Mary Hospital, The University of Hong Kong, Hong Kong, China; 3Vir Biotechnology, Inc., San Francisco, CA; 4Faculty of Medicine, University of Auckland, Auckland, New Zealand

0705221

0705222

0705223

0705224

0705225

0705226

0705227